NVAX vs GSK

For growth investors, Novavax, Inc.

(NVAX) is the stronger pick with 64. 7% revenue growth year-over-year, versus 4. 1% for GSK plc (GSK). Novavax, Inc. (NVAX) offers the better valuation at 4. 0x trailing P/E, making it the more compelling value choice. Analysts rate Novavax, Inc. (NVAX) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 4. 0x versus GSK plc at 6. 7x.

Over the past 5 years, GSK plc (GSK) delivered a total return of +52.

6%, compared to -93. 7% for Novavax, Inc. (NVAX). Over 10 years, the gap is even starker: GSK returned +62. 8% versus NVAX's -89. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), GSK plc (GSK) is the lower-risk stock at 0.

44β versus Novavax, Inc. 's 2. 22β — meaning NVAX is approximately 405% more volatile than GSK relative to the S&P 500.

By revenue growth (latest reported year), Novavax, Inc.

(NVAX) is pulling ahead at 64. 7% versus 4. 1% for GSK plc (GSK). On earnings-per-share growth, the picture is similar: GSK plc grew EPS 348. 4% year-over-year, compared to 306. 5% for Novavax, Inc.. Over a 3-year CAGR, GSK leads at 3. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus 17. 5% for GSK plc — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus 25. 5% for GSK. At the gross margin level — before operating expenses — NVAX leads at 93. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVAX: 78.

0% to $18. 00.

In this comparison, GSK (6.

6% yield) pays a dividend. NVAX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, GSK plc (GSK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

44), 6. 6% yield). Novavax, Inc. (NVAX) carries a higher beta of 2. 22 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GSK: +62. 8%, NVAX: -89. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NVAX is a small-cap high-growth stock; GSK is a mid-cap deep-value stock. GSK pays a dividend while NVAX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.